Editors' Picks
Cross-Border Trust and Transparency: The New Landscape of Bridging the Regulatory Review in the Asia-Pacific
2025-04-23
Unlocking the Gut Code: Japan’s Pharmaceutical Sector Explores the Future of Microbiome Therapeutics
2025-04-23
Advancing Pharmaceutical Regulatory Cooperation in Asia: The Vision and Challenges of GMP Inspection Reliance
2025-04-23
From Cancer to Cosmetics, Physiological to Pathological – The Field of Exosomes Full of Endless Opportunities
Exosomes, with their unique properties, are generating increasing interest for their clinical applications across drug delivery, regenerative medicine, and disease diagnosis. Companies are exploring innovative …
2025-04-22
Special
Unlocking the Gut Code: Japan’s Pharmaceutical Sector Explores the Future of Microbiome Therapeutics
At a recent session hosted by the Japan Pharmaceutical Manufacturers Association (JPMA), experts from academia, industry, and regulatory agencies gathered to delve into the mysteries …
2025-04-23
Eli Lilly’s Orforglipron Shows Phase 3 Success: First Oral GLP-1 Drug for Type 2 Diabetes and Weight Loss
U.S. pharmaceutical giant Eli Lilly and Company announced good news on April 17 that its once-daily oral small molecule GLP-1 receptor agonist. Orforglipron has successfully …
2025-04-21
Exosomes: The Small Couriers Moving Beyond Traditional Drug Delivery
Over the years, drug delivery systems like liposomes, micelles, and synthetic nanoparticles have helped improve the way medications are absorbed and distributed in the body. …
Exosomes: The Small Couriers Moving Beyond Traditional Drug Delivery Read More »
2025-04-17